European Journal of Medicinal Chemistry p. 376 - 388 (2016)
Update date:2022-08-05
Topics:
Wang, Han
Xu, Renyang
Shi, Yongying
Si, Longlong
Jiao, Pingxuan
Fan, Zibo
Han, Xu
Wu, Xingyu
Zhou, Xiaoshu
Yu, Fei
Zhang, Yongmin
Zhang, Liangren
Zhang, Lihe
Zhou, Demin
Xiao, Sulong
Since the influenza viruses can rapidly evolve, it is urgently required to develop novel anti-influenza agents possessing a novel mechanism of action. In our previous study, two pentacyclic triterpene derivatives (Q8 and Y3) have been found to have anti-influenza virus entry activities. Keeping the potential synergy of biological activity of pentacyclic triterpenes and l-ascorbic acid in mind, we synthesized a series of novel l-ascorbic acid-conjugated pentacyclic triterpene derivatives (18-26, 29-31, 35-40 and 42-43). Moreover, we evaluated these novel compounds for their anti-influenza activities against A/WSN/33 virus in MDCK cells. Among all evaluated compounds, the 2,3-O,O-dibenzyl-6-deoxy-l-ascorbic acid-betulinic acid conjugate (30) showed the most significant anti-influenza activity with an EC50 of 8.7 μM, and no cytotoxic effects on MDCK cells were observed. Time-of-addition assay indicated that compound 30 acted at an early stage of the influenza life cycle. Further analyses revealed that influenza virus-induced hemagglutination of chicken red blood cells was inhibited by treatment of compound 30, and the interaction between the influenza hemagglutinin (HA) and compound 30 was determined by surface plasmon resonance (SPR) with a dissociation constant of KD = 3.76 μM. Finally, silico docking studies indicated that compound 30 and its derivative 31 were able to occupy the binding pocket of HA for sialic acid receptor. Collectively, these results suggested that l-ascorbic acid-conjugated pentacyclic triterpenes were promising anti-influenza entry inhibitors, and HA protein associated with viral entry was a promising drug target.
View MoreJIANGXI AIFEIMU TECHNOLOGY CO.,LTD
Contact:+86-570-6040289
Address:FINECHEMICAL PARK,ZIBU TOWN,WANNIAN COUNTY,JIANGXI PROV.,CHINA,ZIP
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Contact:+86-576-84177669, 89189665,89189688,84168770
Address:Jiangkou Development Zone, Huangyan, Taizhou City, Zhejiang
Buffett (China) Holding Co.,Ltd
Contact:4006570891
Address:
Contact:+36(21)2523420
Address:Head office: 1102 Budapest, SZENT LASZLO TER 24/B. 1/1., HUNGARY / CHINA
Zhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
Doi:10.1016/0040-4039(95)01260-O
(1995)Doi:10.1016/0040-4039(95)01236-B
(1995)Doi:10.1007/BF00915683
()Doi:10.1016/0040-4039(94)88049-2
(1994)Doi:10.1016/S0040-4020(97)00643-1
(1997)Doi:10.1002/jlac.199619961219
(1996)